The genetic evidence suggests that higher plasma SAP values are significantly associated with AD and LBD, indicating that targeting SAP may contribute to improved outcomes in neurodegenerative disorders.
The study found that treatment with lecanemab could extend independence in IADLs for an average of 10 months, while donanemab could extend it for 13 months for patients with a baseline CDR-SB of 2. This extension of independence is a meaningful outcome for patients and their families.
The study demonstrated that the repositioned drugs could modify the expression of complement genes in astrocytes, suggesting potential therapeutic benefits for AD patients. Additionally, the framework established a method for better patient stratification, which may enhance treatment efficacy.
Reduction of oligomeric tau at synapses may protect against synaptic loss and cognitive decline in Alzheimer's disease.
Identifying specific symptoms associated with the need for supervision can aid in prognosis and treatment planning, improving the quality of life for both patients and caregivers.
High levels of feasibility and acceptability were reported, with 83.3% of participants completing follow-up surveys. Caregiver behavioral symptom distress decreased significantly from 19.8 to 12.0, and depression scores decreased from 8.8 to 5.4, indicating improved mental health outcomes.
The prototype of CuidaTEXT demonstrated high usability, scoring 97 out of 100 in the System Usability Scale, indicating its potential for widespread implementation in supporting Latino caregivers.
Higher engagement with the text message intervention was associated with increased satisfaction among participants, indicating that more interaction may enhance the perceived value of the support provided.
The study found that a subgroup of patients with more severe cognitive impairment showed a clearer treatment response to donepezil compared to the overall cohort, suggesting improved efficacy in targeted populations.
Cataracts were found to increase the risk of all-cause dementia and vascular dementia, with evidence suggesting that cataract extraction may reduce this risk and potentially improve brain volume.
Individuals exposed to antiherpetic medication showed a tendency towards decreased dementia risk. In one cohort, those diagnosed with herpes but not treated with antiherpetic medication had a higher risk of developing dementia.
MBIs have been associated with reduced stress, improved memory, enhanced cognitive function, and decreased emotional disturbances in individuals with AD/ADRD.
Participants in the CBSDM group showed increased knowledge of dementia risk factors and improved exercise habits. Overall, both groups exhibited moderate to large effect sizes in positive outcomes related to brain health activities.
The study found an increase in dementia diagnoses among those aged 75 and above, indicating some effectiveness of the national policy interventions in improving diagnosis rates, particularly in older cohorts.
There was little evidence that lipid-regulating agents reduced the risk of Alzheimer's disease, but they were associated with an increased risk of other types of dementia.
The study demonstrated that levetiracetam was well tolerated in individuals with Alzheimer's disease without a history of seizures, with no detrimental effects on mood or quality of life.
Reducing soluble p-tau levels may slow the accumulation of tau aggregates and mitigate cognitive decline in early Alzheimer's disease.
Improved implementation of evidence-based dementia care, enhanced early detection, and better management of ADRD symptoms among patients.
Identification of a microbial signature linked to increased risk for neurodegenerative disorders, suggesting potential for microbiome-targeted interventions.
Increased engagement in mid-life activities was associated with better cognitive performance and brain health, particularly in individuals with high dementia risk scores. This suggests a protective effect against cognitive decline and AD.
27.0% of patients on CEIs reported improvement in cognitive symptoms, and 34.8% reported stable symptoms. Among patients on SSRIs, 69.3% reported improvement in neuropsychiatric symptoms, indicating a favorable response to treatment.
The study provides evidence that antipsychotic use in individuals with schizophrenia is associated with an increased risk of developing Alzheimer's disease and other dementias.
Participants reported high satisfaction (87.5%) and a strong likelihood to recommend the training (90.0%). Statistically significant improvements in perceived ADRD care competency were observed post-training, averaging 0.7 points on a 1-5 scale (p<0.05).
Motor task acquisition significantly predicted bilateral hippocampal volume, suggesting its potential as a screening tool for AD risk and progression.